Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
Go back to Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival| Xenetic Biosciences, Inc. (NASDAQ: XBIO) | Delayed: 3.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.00 | 52 Week High | $5.20 | |||
| Open | $3.00 | 52 Week Low | $0.21 | |||
| Day High | $3.00 | P/E | N/A | |||
| Day Low | $3.00 | EPS | $-0.01 | |||
| Volume | 4,433 | |||||
